Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 11, 2015, Pages 2008-2016

  Takenaka, Katsuto ^a   Nishida, Tetsuya ^b   Asano Mori, Yuki ^c   Oshima, Kumi ^d   Ohashi, Kazuteru ^e   Mori, Takehiko ^f   Kanamori, Heiwa ^g   Miyamura, Koichi ^h   Kato, Chiaki ⁱ   Kobayashi, Naoki ^j   Uchida, Naoyuki ^c   Nakamae, Hirohisa ^k   Ichinohe, Tatsuo ^d   Morishima, Yasuo ^l   Suzuki, Ritsuro ^b   Yamaguchi, Takuhiro ^m   Fukuda, Takahiro ⁿ  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TORANOMON HOSPITAL   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

^e TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^f KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KANAGAWA CANCER CENTER   (Japan)

^h JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

ⁱ Meitetsu Hospital   (Japan)

^j SAPPORO HOKUYU HOSPITAL   (Japan)

^k OSAKA CITY UNIVERSITY HOSPITAL   (Japan)

^l AICHI CANCER CENTER HOSPITAL   (Japan)

^m TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁿ NATIONAL CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

Allogeneic hematopoietic stem cell transplantation; Cytomegalovirus; Nonrelapse mortality; Risk of relapse

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; MYELOABLATIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADOPTIVE TRANSFER; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; ENGRAFTMENT; FEMALE; HLA MATCHING; HUMAN; IMMUNOSTIMULATION; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORTALITY; MYELODYSPLASTIC SYNDROME; NONHUMAN; RELAPSE; RISK FACTOR; RISK REDUCTION; T LYMPHOCYTE; UNRELATED DONORS; VIRUS REACTIVATION; ALLOTRANSPLANTATION; CYTOMEGALOVIRUS INFECTIONS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RETROSPECTIVE STUDY; TRANSPLANTATION CONDITIONING; VIROLOGY; VIRUS ACTIVATION;

ADOLESCENT; ADULT; AGED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JAPAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS; VIRUS ACTIVATION;

EID: 84943449774     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.07.019     Document Type: Article

References (40)

1. Boeckh M., Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004, 103:2003-2008.
2. Boeckh M., Nichols W.G., Papanicolaou G., et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003, 9:543-558.
3. Ljungman P., Hakki M., Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 2010, 24:319-337.
4. Ljungman P., de la Camara R., Cordonnier C., et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 2008, 42:227-240.
5. Boeckh M., Ljungman P. How I treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113:5711-5719.
6. Boeckh M., Gooley T.A., Myerson D., et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
7. Yanada M., Yamamoto K., Emi N., et al. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003, 32:801-807.
8. Nichols W.G., Corey L., Gooley T., et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002, 185:273-282.
9. Lonnqvist B., Ringden O., Ljungman P., et al. Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br J Haematol 1986, 63:671-679.
10. Behrendt C.E., Rosenthal J., Bolotin E., et al. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant 2009, 15:54-60.
11. Remberger M., Ringdén O. Survival after bone-marrow transplantation. Lancet 2002, 359:888.
12. Ljungman P., Brand R., Einsele H., et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003, 102:4255-4260.
13. Kollman C. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
14. Farina L., Bruno B., Patriarca F., et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia 2009, 23:1131-1138.
15. Schmidt-Hieber M., Labopin M., Beelen D., et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood 2013, 122:3359-3364.
16. Elmaagacli A.H., Steckel N.K., Koldehoff M., et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 2011, 118:1402-1412.
17. Green M.L., Leisenring W.M., Xie H., et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 2013, 122:1316-1324.
18. Ito S., Pophali P., Co W., et al. CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transplant 2013, 48:1313-1316.
19. Jang J.E., Kim S.J., Cheong J.W., et al. Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. Ann Hematol 2015, 94:275-282.
20. Mariotti J., Maura F., Spina F., et al. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2014, 20:885-890.
21. Jeljeli M., Guerin-El Khourouj V., Porcher R., et al. Relationship between cytomegalovirus (CMV) reactivation, CMV-driven immunity, overall immune recovery and graft-versus-leukaemia effect in children. Br J Haematol 2014, 166:229-239.
22. Manjappa S., Bhamidipati P.K., Stokerl-Goldstein K.E., et al. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transplant 2014, 20:46-52.
23. Atsuta Y., Suzuki R., Yoshimi A., et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol 2007, 86:269-274.
24. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
25. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
26. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
27. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
28. Gray R.J. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
29. Fine J.P., Gray R.J. A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc 1999, 94:456-509.
30. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013, 48:452-458.
31. Sasazuki T., Juji T., Morishima Y., et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998, 339:1177-1185.
32. Kanda Y., Kanda J., Atsuta Y., et al. Impact of a single human leucocyte antigen (HLA) allele mismatch on the outcome of unrelated bone marrow transplantation over two time periods. A retrospective analysis of 3003 patients from the HLA Working Group of the Japan Society for Blood and Marrow Transplantation. Br J Haematol 2013, 161:566-577.
33. Ramanathan M., Teira P., Battiwalla M., et al. Early CMV reactivation still remains a cause of increased transplant related mortality in the current era: a CIBMTR analysis [abstract]. Blood 2014, 124:47.
34. Thomson K.J., Mackinnon S., Peggs K.S. CMV-specific cellular therapy for acute myeloid leukemia?. Blood 2012, 119:1088-1090. author reply 90-1.
35. Foley B., Cooley S., Verneris M.R., et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012, 119:2665-2674.
36. Della Chiesa M., Falco M., Muccio L., et al. Impact of HCMV infection on NK cell development and function after HSCT. Front Immunol 2013, 4:458.
37. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
38. Challa-Malladi M., Lieu Y.K., Califano O., et al. Combined genetic inactivation of beta2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011, 20:728-740.
39. Venstrom J.M., Pittari G., Gooley T.A., et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012, 367:805-816.
40. Kharfan-Dabaja M.A., Boeckh M., Wilck M.B., et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012, 12:290-299.